Article
COMT and Neuregulin 1 Markers for Personalized Treatment of Schizophrenia Spectrum Disorders Treated with Risperidone Monotherapy.
Biomolecules - 29 Jun 2024
Bondrescu Mariana, Dehelean Liana, Farcas Simona Sorina, Papava Ion, Nicoras Vlad, Mager Dana Violeta, Grecescu Anca Eliza, Podaru Petre Adrian, Andreescu Nicoleta Ioana
Abstract excerpt
Pharmacogenetic markers are current targets for the personalized treatment of psychosis. Limited data exist on COMT and NRG1 polymorphisms in relation to risperidone treatment. This study focuses on the impact of COMT rs4680 and NRG1 (rs35753505, rs3924999) polymorphisms on risperidone treatment in schizophrenia spectrum disorders (SSDs). This study included 103 subjects with SSD treated with risperidone...
Topics
Join the communities discussing this publication.
